Ziopharm's darinaparsin set for Asian development under Solasia deal
This article was originally published in Scrip
Executive Summary
The Japanese venture Solasia Pharma has expanded its pipeline with the acquisition of exclusive development and commercialisation rights in 13 Asian markets to Ziopharm Oncology's anticancer Zinapar (darinaparsin).